Overview
TB-500 is a synthetic peptide associated with Thymosin Beta-4 (TΒ4), a naturally occurring protein that helps regulate actin — the structural protein that drives cell shape, movement and division. In the literature TB-500 is usually framed as a synthetic version or fragment-like analog connected to Thymosin Beta-4 research rather than a single, standardized molecule. Because it sits close to a well-characterized repair protein, it appears frequently in studies that examine how cells migrate, build new tissue and recover after injury.
How TB-500 Works
The proposed mechanism centers on actin binding. Thymosin Beta-4 sequesters actin monomers and influences how the cytoskeleton is remodeled, which in turn affects cell migration, new blood-vessel formation (angiogenesis) and inflammatory signalling. By acting along these same pathways, TB-500 is hypothesized to help cells reorganize and relocate during tissue repair. It is worth stressing that a biologically plausible mechanism is not the same as a proven clinical effect — the pathway is well described, but outcomes in living subjects remain a research question.
What the Research Explores
- Tendon, ligament and connective-tissue recovery models.
- Wound healing and broader tissue-repair pathways.
- Actin regulation and cytoskeletal remodeling at the cellular level.
- Angiogenesis and cell-migration dynamics.
- Cardiac and vascular repair after injury, plus inflammation modulation.
Forms & Handling
TB-500 is typically supplied as a lyophilized powder in vial sizes such as 10 mg, 20 mg and 30 mg. For laboratory work it is reconstituted with bacteriostatic or sterile water, then kept refrigerated once in solution; the sealed powder is stored cold and away from light until use. See the dosing protocols below for the reconstitution math expressed in insulin-syringe units.
Safety & Research Notes
TB-500 is an investigational research compound with no approved human or veterinary use and no established safety profile for administration. Much of what circulates about it reflects proposed uses or anecdotal claims rather than approved indications, and it appears on anti-doping prohibited lists. The published work is confined to laboratory and pre-clinical contexts, so anything described here is mechanistic background only — not a usage recommendation.
References
- UniProt entry P62328 — Thymosin Beta-4, sequence and functional annotation. UniProt Knowledgebase. uniprot.org/uniprotkb/P62328/entry
- Goldstein AL, et al. Thymosin Beta-4: actin sequestration and roles in cell migration and tissue repair. Annals of the New York Academy of Sciences. doi.org/10.1196/annals.1408.013
- Bock-Marquette I, et al. Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration and survival. Nature. doi.org/10.1038/nature03000
- Thymosin beta 4 — registered and investigational studies. ClinicalTrials.gov. clinicaltrials.gov/search?term=thymosin beta 4